61718-82-9 Usage
Description
Fluvoxamine maleate is the most recent of the serotonin-specific antidepressants
to reach the market. In vitro and in vivo animal experiments have shown
fluvoxamine to have a marked effect on 5-HT mediated processes and little effect
on norepinephrine. Clinical trials suggest similar efficacy to imipramine and
clomipramine with a somewhat lower incidence of side effects, especially anticholinergic
effects. Fluvoxamine, in contrast to the tricyclic antidepressants,
does not appear to produce heart rate increase, postural hypotension or prolongation
of the intraventricular conduction time and QT interval.
Chemical Properties
Crystalline Solid
Originator
Duphar (Netherlands)
Uses
Different sources of media describe the Uses of 61718-82-9 differently. You can refer to the following data:
1. A selective serotonin reuptake inhibitor (SSRI) used as an anti-depressant. Antiobsessional.
2. nonsteroidal anti-inflammatory reduces pain and inflammation in eyes
3. Anxiety disorder
4. Fluvoxamine maleate has been used as a test compound to determine the solubility and effective blood-brain barrier permeability.(2)
Brand name
Luvox (Solvay Pharmaceuticals);FLOXYFRAL.
Therapeutic Function
Antidepressant
General Description
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
Biological Activity
Selective serotonin reuptake inhibitor; antidepressant. Binds to the human 5-HT transporter with a K i of 1.6 nmol/l. Also available as part of the Serotonin Uptake Inhibitor Tocriset? .
Biochem/physiol Actions
Fluvoxamine maleate is a selective neuronal serotonin reuptake inhibitor. It functions as an antidepressant and anti-obsessive agent. It is useful in treating obsessive compulsive disorder and panic disorder.
Clinical Use
SSRI antidepressant:DepressionObsessive compulsive disorder
Veterinary Drugs and Treatments
Fluvoxamine may be considered for use in treating a variety of behavior-
related diagnoses in dogs and cats, including aggression and
stereotypic behaviors (and other obsessive-compulsive behaviors).
Drug interactions
Potentially hazardous interactions with other drugsAminophylline and theophylline: increased
aminophylline and theophylline concentrations
- avoid; if not possible, halve aminophylline or
theophylline dose and monitor levels.Analgesics: increased risk of bleeding with aspirin
and NSAIDs; risk of CNS toxicity increased with
tramadol; concentration of methadone possibly
increased.Anti-arrhythmics: increased risk of toxicity with
mexiletine.Anticoagulants: effect of coumarins possibly
enhanced; possibly increased risk of bleeding with
dabigatran.Antidepressants: avoid with reboxetine, MAOIs,
moclobemide and St John’s wort; possibly enhanced
serotonergic effects with mirtazapine; fluvoxamine
inhibits metabolism of duloxetine - avoid; can
increase tricyclics concentration; metabolism of
agomelatine reduced; possible increased risk of
convulsions with vortioxetine.Antiepileptics: antagonise anticonvulsant threshold;
concentration of carbamazepine, fosphenytoin and
phenytoin increased.Antimalarials: avoid with artemether/lumefantrine
and piperaquine with artenimol.Antipsychotics: concentration of asenapine,
haloperidol, clozapine and olanzapine increased;
increased risk of ventricular arrhythmias with
droperidol and possibly pimozide - avoid.Antivirals: concentration possibly increased by
ritonavir.Ciclosporin: may increase ciclosporin concentration.Clopidogrel: possibly reduced antiplatelet effect.Cytotoxics: concentration of pomalidomide
increasedDapoxetine: possible increased risk of serotonergic
effects - avoid.Dopaminergics: increased risk of CNS toxicity with
rasagiline - avoid; hypertension and CNS excitation
with selegiline - avoid. 5HT1
agonists: risk of CNS toxicity increased with
sumatriptan; possibly increased risk of serotonergic
effects with naratriptan; inhibits metabolism
of frovatriptan; possibly inhibits metabolism of
zolmitriptan - reduce zolmitriptan dose.Linezolid: use with care, possibly increased risk of
side effects.Lithium: increased risk of CNS effects - monitor
levels.Melatonin: concentration of melatonin increased -
avoid.Methylthioninium: risk of CNS toxicity - avoid if
possible.Muscle relaxants: increased risk of toxicity with
tizanidine - avoidPirfenidone: concentration of pirfenidone increased
- avoid.
Metabolism
Fluvoxamine undergoes extensive hepatic transformation
by CYP2D6, mainly via oxidative demethylation, into
at least 9 metabolites. The 2 major metabolites showed
negligible pharmacological activity. The other metabolites
are not expected to be pharmacologically active.Excretion is mainly in the urine; about 2% of a dose is
excreted as unchanged drug.
Check Digit Verification of cas no
The CAS Registry Mumber 61718-82-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,1,7,1 and 8 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 61718-82:
(7*6)+(6*1)+(5*7)+(4*1)+(3*8)+(2*8)+(1*2)=129
129 % 10 = 9
So 61718-82-9 is a valid CAS Registry Number.
InChI:InChI=1/C15H21F3N2O2.C4H4O4/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18;5-3(6)1-2-4(7)8/h5-8H,2-4,9-11,19H2,1H3;1-2H,(H,5,6)(H,7,8)/b20-14+;2-1-
61718-82-9Relevant articles and documents
AN IMPROVED PROCESS FOR THE PREPARATION OF FLUVOXAMINE MALEATE
-
Paragraph 0045; 0046; 0047, (2016/07/05)
The present invention relates to an industrially feasible and economically viable process for the preparation of fluvoxamine maleate of formula I.
